RXi Pharmaceuticals Corporation Begins Trading on OTCQX®
NEW YORK, June 19, 2013
NEW YORK, June 19, 2013 /PRNewswire/ --OTC Markets Group Inc. (OTCQX: OTCM),
operator of Open, Transparent and Connected financial marketplaces, today
announced that RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology
company focused on discovering, developing, and commercializing innovative
therapies based on its proprietary, next-generation RNAi platform, has
upgraded to OTCQX®, the best marketplace with qualified companies.
RXi Pharmaceuticals will begin trading today on OTCQX U.S., a segment of the
OTCQX marketplace reserved for high-quality U.S. companies that meet financial
standards, undergo management reviews and provide timely news and disclosure
to investors. Investors can find current financial disclosure and Real-Time
Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome RXi Pharmaceuticals to the OTCQX marketplace," said
R. Cromwell Coulson, President and CEO of OTC Markets Group. "RXi exemplifies
the high caliber growing U.S. companies trading on OTCQX with a management
team that hails from leading drug companies like Johnson & Johnson, Galena
Biopharma and Cytomed, and an advisory board that includes a Nobel Laureate in
Medicine. We look forward to supporting the RXi team as they continue to grow
the company and provide a robust, transparent, public market for their
"Upgrading to the OTCQX marketplace is ideal for RXi, allowing us to
distinguish ourselves in the market and enhance our visibility with
investors," said Dr. Geert Cauwenbergh, President and CEO of RXi
Pharmaceuticals. "With OTCQX, we can clearly convey our qualifications to the
financial markets and ensure our shareholders receive high-quality disclosure,
transparent trading and easy access through their regulated U.S.
Roth Capital Partners, LLC will serve as RXi Pharmaceutical's Designated
Advisor for Disclosure ("DAD") on OTCQX, responsible for providing
professional guidance on OTCQX requirements.
RXi Pharmaceuticals is a biotechnology company focused on discovering,
developing, and commercializing innovative therapies based on its proprietary,
next-generation RNAi platform. Therapeutics that use RNA interference, or
"RNAi," have great promise because of their ability to "silence" or
down-regulate, the expression of a specific gene that may be expressed in a
disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109,
entered into RXi's first human trial in 2012. RXI-109 targets connective
tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation,
and is initially being developed to reduce or inhibit scar formation in the
skin following surgery.
RXi Pharmaceuticals trades in the U.S. on OTCQX under the symbol "RXII."
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers that provide
liquidity and execution services for a wide spectrum of securities. We
organize these securities into marketplaces to better inform investors of
opportunities and risks – OTCQX®, The Best Marketplace with Qualified
Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting
Companies; and OTC Pink®, The Open Marketplace with Variable Reporting
Companies. Our data-driven platform enables investors to easily trade through
the broker of their choice at the best possible price and empowers a broad
range of companies to improve the quality and availability of information for
their investors. To learn more about how we create better informed and more
efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated
Subscribe to the OTC Markets RSS Feed
SOURCE OTC Markets Group Inc.
Contact: Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
Press spacebar to pause and continue. Press esc to stop.